News for ARS Pharmaceuticals Inc Stock (SPRY)

ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)

GlobeNewsWire • Saturday

Wall Street Analysts Think ARS Pharmaceuticals, Inc. (SPRY) Could Surge 67.56%: Read This Before Placing a Bet

Zacks Investment Research • Wednesday

ARS Pharmaceuticals, Inc. Is Being Investigated For Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

Accesswire • Monday

The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Securities Law Violations

Accesswire • 11/03/24

ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

Accesswire • 11/02/24

The Schall Law Firm Encourages Shareholders To Join An Inquiry Into ARS Pharmaceuticals Inc For Securities Law Violations

Accesswire • 10/31/24

ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm

Accesswire • 10/30/24

Here's Why 'Trend' Investors Would Love Betting on ARS Pharmaceuticals, Inc. (SPRY)

Zacks Investment Research • 10/30/24

ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

GlobeNewsWire • 10/24/24

ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Affected Investors Are Urged To Reach Out To The Schall Law Firm

Accesswire • 10/23/24

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm

Accesswire • 10/19/24

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

Accesswire • 10/17/24

Wall Street Analysts Believe ARS Pharmaceuticals, Inc. (SPRY) Could Rally 76.79%: Here's is How to Trade

Zacks Investment Research • 10/14/24

ARS Pharmaceuticals, Inc. (SPRY) is on the Move, Here's Why the Trend Could be Sustainable

Zacks Investment Research • 10/14/24

The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Securities Related Infractions

Accesswire • 10/08/24

The Schall Law Firm Invites Shareholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Securities Law Violations

Accesswire • 10/06/24

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Impacted Investors Are Encouraged To Reach Out To The Schall Law Firm

Accesswire • 10/05/24

The Schall Law Firm Urges Shareholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Securities Law Violations

Accesswire • 10/04/24

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Are Invited To Assist The Schall Law Firm

Accesswire • 10/03/24

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm

Accesswire • 10/01/24

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Are Invited To Contact The Schall Law Firm

Accesswire • 09/29/24

The Schall Law Firm Urges Stockholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Violating Securities Laws

Accesswire • 09/28/24

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Investors Are Invited To Assist The Schall Law Firm

Accesswire • 09/27/24

The Schall Law Firm Invites Stockholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Violating Securities Laws

Accesswire • 09/24/24

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Should Contact The Schall Law Firm

Accesswire • 09/23/24